CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- 4 Open-market buy Director bought 10,000 shares at $3.10 ($31,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4/A Open-market buy 10% owner bought 10,136 shares at an average $4.78 ($48,487)
- 4 Open-market buy 10% owner bought 10,136 shares at an average $4.78 ($48,487)
- 4 Open-market buy Director bought 10,000 shares at $4.25 ($42,500)
- 4 Open-market buy Director bought 10,000 shares at $4.46 ($44,555)
- 4/A Insider Changes in Ownership
- 5 Insider Annual Insider Trading Report
- 4 Open-market buy 10% owner bought 24,031 shares at $4.96 ($119,271)
- 4 Shares withheld for taxes Chf Scientific Operations Off gave up 4,603 shares (to pay taxes)
- 4 Shares withheld for taxes CEO and President gave up 5,080 shares (to pay taxes)
- 4 Grant or award Chief Medical Officer acquired 13,500 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 7 of 20 · 382 filings